{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:14:35Z","timestamp":1788200075062,"version":"build-2803163510"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["53559"],"award-info":[{"award-number":["53559"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Posaconazole is indicated for prophylaxis and treatment of invasive aspergillosis. Therapeutic drug monitoring (<jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content>) of posaconazole is used to optimise drug exposure. The aim of this study was to analyse and describe the <jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content> practices and exposure of posaconazole tablets. Patients who received posaconazole for treatment or prophylaxis of fungal infections were included in the study. The following therapeutic window was defined: if concentration was low (&lt;0.7\u00a0mg\/L for prophylaxis or\u00a0&lt;\u00a01.5\u00a0mg\/L for treatment) or high (&gt;3.75\u00a0mg\/L), the hospital pharmacist provided the physician with dosage advice, which implementation to patient care was analysed. A longitudinal analysis was performed to analyse if different confounding variables had an effect on posaconazole concentrations. Forty\u2010seven patients were enrolled resulting in 217 posaconazole trough concentrations. A median of 3 (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 1\u20107) samples was measured per patient. The median concentration was 1.7\u00a0mg\/L (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 0.8\u20102.7) for prophylaxis and 1.76\u00a0mg\/L (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 1.3\u20102.3) for treatment. Overall, 78 posaconazole concentrations were out of the therapeutic window. For 45 (54%) of these concentrations, a dosage change was recommended. In the longitudinal analysis, the laboratory markers and patient baseline variables did not have an effect on posaconazole concentrations. Adequate posaconazole exposure was shown in 64% (affected 28 patients) of the measured concentrations. <jats:styled-content style=\"fixed-case\">TDM<\/jats:styled-content> practice of posaconazole can be improved by increasing the implementation rate of dose recommendation by a multidisciplinary antifungal stewardship team.<\/jats:p>","DOI":"10.1111\/myc.12948","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T14:29:28Z","timestamp":1559226568000},"page":"698-705","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations"],"prefix":"10.1111","volume":"62","author":[{"given":"Anne\u2010Grete","family":"M\u00e4rtson","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Veringa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Computer Science Eindhoven University of Technology Eindhoven The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University Medical Center Groningen University of Groningen Groningen The Netherlands"},{"name":"Department of Pulmonary Diseases and Tuberculosis University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert F. R.","family":"Span","sequence":"additional","affiliation":[{"name":"Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan\u2010Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen University of Groningen Groningen The Netherlands"},{"name":"Faculty of Medicine and Health, School of Pharmacy The University of Sydney Westmead Hospital Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0808853"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.838217"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70297-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.658-666.2006"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000235"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000334"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/597110"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.04.007"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_2_8_17_1","article-title":"Posaconazole exposure\u2010response relationship: evaluating the utility of therapeutic drug monitoring","volume":"56","author":"Dolton MJ","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03777-14"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02686-13"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02448-13"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-09"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00150-10"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-12"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01325-10"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw099"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx029"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-016-0255-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.01.006"},{"issue":"1","key":"e_1_2_8_29_1","first-page":"17","article-title":"Relevance of liver failure for anti\u2010infective agents: from pharmacokinetic alterations to dosage adjustments","volume":"2","author":"B\u03cbdingen FV","year":"2014","journal-title":"Ther Adv Infect Dis"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.11.017"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv380"},{"key":"e_1_2_8_32_1","unstructured":"MerckS DohmeBV.Merck Sharp & Dohme Ltd. Noxafil (posaconazole) \u2010 summary of product characteristics.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000610\/WC500037784.pdf. Published 2017. Accessed December 11 2017."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2003.49999"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx440"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02655-17"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12339"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13707"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2523-2"},{"issue":"6","key":"e_1_2_8_39_1","first-page":"66","article-title":"Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease","volume":"37","author":"Elst KCM","year":"2015","journal-title":"Ther Drug Monit"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/665010"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12622"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp120482"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7010020"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt241"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.12948","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.12948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T09:09:56Z","timestamp":1693991396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.12948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1111\/myc.12948"],"URL":"https:\/\/doi.org\/10.1111\/myc.12948","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"2019-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}